Matches in Wikidata for { <http://www.wikidata.org/entity/Q83794127> ?p ?o ?g. }
Showing items 1 to 33 of
33
with 100 items per page.
- Q83794127 description "clinical trial" @default.
- Q83794127 description "ensayu clínicu" @default.
- Q83794127 description "klinisch onderzoek" @default.
- Q83794127 description "клінічне випробування" @default.
- Q83794127 name "Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)" @default.
- Q83794127 name "Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)" @default.
- Q83794127 type Item @default.
- Q83794127 label "Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)" @default.
- Q83794127 label "Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)" @default.
- Q83794127 prefLabel "Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)" @default.
- Q83794127 prefLabel "Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)" @default.
- Q83794127 P1050 Q83794127-33C1F1EF-39D9-40FB-BE11-3454D987B89D @default.
- Q83794127 P1050 Q83794127-E96727E1-0F37-40DF-85AC-BF24201E9012 @default.
- Q83794127 P1132 Q83794127-FD68C345-DA9E-4129-9B69-DCCC4E2E7113 @default.
- Q83794127 P1476 Q83794127-F96C4AF9-6140-4A61-ABC4-EF50B0022D89 @default.
- Q83794127 P2899 Q83794127-BBA9038D-DCE5-4F5C-9655-C35A66E58438 @default.
- Q83794127 P3098 Q83794127-D438757A-BAA8-46D2-AE68-FCB5F96E9678 @default.
- Q83794127 P31 Q83794127-C2A21603-E1D0-4EE3-8C2B-513698D381A9 @default.
- Q83794127 P580 Q83794127-64E57BE0-E8AD-4CF5-A1F7-FDE2871F8D41 @default.
- Q83794127 P582 Q83794127-9224FF6A-9B6C-4C02-BCE7-F130FD547D70 @default.
- Q83794127 P6099 Q83794127-3693B672-2856-4089-95E9-DB778115047D @default.
- Q83794127 P8363 Q83794127-7A531DF9-86FD-4328-9F52-C958564B61DB @default.
- Q83794127 P1050 Q1546498 @default.
- Q83794127 P1050 Q657193 @default.
- Q83794127 P1132 "+50" @default.
- Q83794127 P1476 "A Single-Arm, Open-Label, Pilot Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)" @default.
- Q83794127 P2899 "+18" @default.
- Q83794127 P3098 "NCT04216589" @default.
- Q83794127 P31 Q30612 @default.
- Q83794127 P580 "2020-06-29T00:00:00Z" @default.
- Q83794127 P582 "2021-08-29T00:00:00Z" @default.
- Q83794127 P6099 Q42824440 @default.
- Q83794127 P8363 Q78089383 @default.